Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. The failure of hormonal and cytotoxic chemotherapy in the treatment of recurrent meningioma and increasing understanding of potential molecular targets in meningioma has resulted in multiple studies utilizing single-agent targeted therapy directed at biologically relevant signaling pathways, such as [[somatostatin]] (Sandostatin(®) LAR, SOM230c), PDGF ([[imatinib]]), EGF ([[erlotinib]]) and VEGF (sunitinib and [[vatalanib]]) ((Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev Neurother. 2011 Oct;11(10):1425-32. doi: 10.1586/ern.11.38. Review. PubMed PMID: 21955199. )). vatalanib.txt Last modified: 2024/06/07 02:59by 127.0.0.1